HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors.
HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors.
HONG KONG – Chinese biopharma company Huya Bioscience International LLC extended its global partnership and commercialization business model to South Korea, looking to replicate the success it has had taking promising compounds from one country – mostly China – and developing them elsewhere.
HONG KONG – As a part of efforts to encourage innovation and internationalization of biotech companies, the Chinese government is now actively encouraging outbound investment from Chinese enterprises. The aim is to get Chinese companies to sell products abroad and, in turn, bring back advanced technologies. The push could generate significant opportunities, but will require companies to overcome a series of practical challenges and provide products of uniformly high quality.
HONG KONG – As a part of efforts to encourage innovation and internationalization of biotech companies, the Chinese government is now actively encouraging outbound investment from Chinese enterprises.
HONG KONG – The Malaysian government is setting a five-year data protection structure for biologics in the country under the terms of the Trans-Pacific Partnership (TPP). That could mean more expensive drugs for the people and better protection for drugmakers.
HONG KONG – 3Sbio Inc., a biopharmaceutical company that has returned to a stock market in China after delisting abroad, has now taken a further step in its newfound home market by acquiring shares of a leading biosimilar monoclonal antibody (MAb) maker as part of an effort to build the largest biological drug platform in China.
HONG KONG – 3Sbio Inc., a biopharmaceutical company that has returned to a stock market in China after delisting abroad, has now taken a further step in its newfound home market by acquiring shares of a leading biosimilar monoclonal antibody (MAb) maker as part of an effort to build the largest biological drug platform in China.
